Cargando…
Detection of Tumour-Targeted IRDye800CW Tracer with Commercially Available Laparoscopic Surgical Systems
(1) Introduction: Near-infrared fluorescence (NIRF) combined with tumour-targeted tracers, such as bevacizumab-800CW, could aid surgical decision-making. This study explored the use of IRDye800CW, conjugated to bevacizumab, with four commercially available NIRF laparoscopes optimised for indocyanine...
Autores principales: | Sikkenk, Daan J., Sterkenburg, Andrea J., Schmidt, Iris, Gorpas, Dimitris, Nagengast, Wouter B., Consten, Esther C. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178288/ https://www.ncbi.nlm.nih.gov/pubmed/37174982 http://dx.doi.org/10.3390/diagnostics13091591 |
Ejemplares similares
-
Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers
por: Gao, Rebecca W., et al.
Publicado: (2018) -
Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention in the sentinel lymph node
por: Heuveling, Derrek A., et al.
Publicado: (2012) -
Near-Infrared Fluorescence Imaging of EGFR-Overexpressing Tumors in the Mouse Xenograft Model Using scFv-IRDye800CW and Cetuximab-IRDye800CW
por: Amini, Abolfazl, et al.
Publicado: (2022) -
Single-Dose Intravenous Toxicity Study of IRDye 800CW in Sprague-Dawley Rats
por: Marshall, Milton V., et al.
Publicado: (2010) -
Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
por: Bernhard, Wendy, et al.
Publicado: (2021)